NCT03656666View on ClinicalTrials.gov

The AP-GELP Study: A Clinical Trial on the Effects of Apremilast in Female Genital Erosive Lichen Planus

PHASE2UnknownINTERVENTIONAL

Enrollment

42

Participants

Timeline

Start Date

September 24, 2019

Primary Completion Date

November 30, 2022

Study Completion Date

December 31, 2023

Conditions

Lichen Planus of VulvaFemale Genital Disease

Interventions

DRUG

Apremilast

Apremilast oral tablets

DRUG

Placebo

Placebo oral tablets

Trial Locations (1)

0424

Oslo University Hospital HF, Oslo

Sponsors

Collaborators (2)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

collaborator

Amgen

INDUSTRY

lead

Oslo University Hospital

OTHER